| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Psychiatry (J.J.M.H.S., A.H., A.H.P.L., P.M.J.C.K., H.M.V.P.) and Cardiology (E.C.C., P.M.J.C.K., M.F.P.M.H.J.J.W.), University Hospital Maastricht; Department of Psychiatry (J.J.M.H.S., A.H., R.L.), University of Maastricht; and Eli Lilly Netherlands (H.G.T.-Q.), Nieuwegein, The Netherlands.
Address reprint requests to: Jacqueline J. M. H. Strik, MD, University Hospital Maastricht/University of Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands. Email: Jacqueline.Strik{at}spsy.azm.nl
OBJECTIVE: Depression and hostility are significant risk factors for mortality and morbidity after myocardial infarction (MI). Much research is still needed to identify effective ways to reduce emotional distress in patients with cardiovascular disease. This double-blind, placebo-controlled study investigated the efficacy and safety of the antidepressant fluoxetine in patients with depression after their first MI.
METHODS: Fifty-four patients with major depression after MI were randomly assigned to receive a flexible-dose regimen of fluoxetine or placebo for the first 9 weeks of a double-blind, placebo-controlled trial. Patients without serious adverse effects who wished to continue participating in the study were given fluoxetine or placebo for an additional 16 weeks. To evaluate the efficacy of fluoxetine, the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Hostility Scale of the 90-item Symptom Check List (SCL-90) were used as primary measures of outcome. To evaluate the safety of fluoxetine, cardiac function was measured before and after treatment with echocardiography and electrocardiography.
RESULTS: The a priori difference in antidepressive efficacy (4-point difference in HAMD-17 scores between the fluoxetine and placebo groups) was not met. However, the response rate among patients receiving fluoxetine was significantly greater than that among patients receiving placebo at week 25 (48 vs. 26%, p = .05). Among patients with mild depression (HAMD-17 score 
21), HAMD-17 scores were significantly different (p < .05) between the fluoxetine and placebo groups at weeks 9 (by 5.4 points) and 25 (by 5.8 points). Also, hostility scores at week 25 were significantly reduced among patients receiving fluoxetine (p = .02). Analysis of electrocardiographic and echocardiographic parameters revealed no decrease in cardiac function as a result of treatment with fluoxetine.
CONCLUSIONS: Although the overall difference between the fluoxetine and placebo groups was not significant, there was a trend favoring fluoxetine in this relatively small sample. The response rate in the group receiving fluoxetine was comparable with that observed in other studies of patients with cardiovascular disease. In addition, fluoxetine seemed to be particularly effective in patients with mild depression and was associated with a statistically significant reduction in hostility. The results of this study suggest that fluoxetine can be safely used to treat patients with post-MI depression beginning 3 months after the event.
Key Words: fluoxetine • major depression • myocardial infarction.
Abbreviations: ASAT = aspartate aminotransferase; ATVI = aortic time velocity integral; DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, third edition revised; E/A ratio = early or passive/active or late mitral inflow ratio; HAMD-17 = 17-item Hamilton Depression Scale; LVEF = left ventricular ejection fraction; MI = myocardial infarction; QTc = corrected QT interval; SCL-90 = 90-item Symptom Check List; SSRI = selective serotonergic reuptake inhibitor.
This article has been cited by other articles:
 |
|
 |
|
  B. Wann, T. Bah, S Kaloustian, M Boucher, A. Dufort, N Le Marec, R Godbout, and G Rousseau Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline J Psychopharmacol, June 1, 2009; 23(4): 451 - 459. [Abstract] [PDF]
|
|
|
|
 |
|
 Post-Myocardial Infarction Depression Clinical Pra AAFP Guideline for the Detection and Management of Post-Myocardial Infarction Depression Ann. Fam. Med, January 1, 2009; 7(1): 71 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 734 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Thombs, P. de Jonge, J. C. Coyne, M. A. Whooley, N. Frasure-Smith, A. J. Mitchell, M. Zuidersma, C. Eze-Nliam, B. B. Lima, C. G. Smith, et al. Depression Screening and Patient Outcomes in Cardiovascular Care: A Systematic Review JAMA, November 12, 2008; 300(18): 2161 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Roy-Byrne, K. W. Davidson, R. C. Kessler, G. J.G. Asmundson, R. D. Goodwin, L. Kubzansky, R. B. Lydiard, M. J. Massie, W. Katon, S. K. Laden, et al. Anxiety Disorders and Comorbid Medical Illness Focus, September 1, 2008; 6(4): 467 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol, June 1, 2008; 22(4): 343 - 396. [Abstract] [PDF]
|
|
|
|
 |
|
 Depression, antidepressants and heart disease DTB, April 1, 2008; 46(4): 29 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fraguas Jr., D. V. Iosifescu, J. Alpert, S. R. Wisniewski, J. L. Barkin, M. H. Trivedi, A J. Rush, and M. Fava Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study Psychosomatics, October 1, 2007; 48(5): 418 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Jonge, A. Honig, J. P. van Melle, A. H. Schene, A. M.G. Kuyper, D. Tulner, A. Schins, J. Ormel, and The MIND-IT Investigators Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events Am J Psychiatry, September 1, 2007; 164(9): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Honig, A. M. G. Kuyper, A. H. Schene, J. P. van Melle, P. de Jonge, D. M. Tulner, A. Schins, H. J. G. M. Crijns, P. M. J. C. Kuijpers, H. Vossen, et al. Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled Trial With Mirtazapine Psychosom Med, September 1, 2007; 69(7): 606 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lesperance, N. Frasure-Smith, D. Koszycki, M.-A. Laliberte, L. T. van Zyl, B. Baker, J. R. Swenson, K. Ghatavi, B. L. Abramson, P. Dorian, et al. Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial JAMA, January 24, 2007; 297(4): 367 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Roose and M. Miyazaki Pharmacologic Treatment of Depression in Patients With Heart Disease Psychosom Med, May 1, 2005; 67(Supplement_1): S54 - S57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Ketterer, G. Mahr, J. J. Cao, M. Hudson, S. Smith, and W. Knysz What's "Unstable" in Unstable Angina? Psychosomatics, June 1, 2004; 45(3): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J C Davies, P. R Jackson, J. Potokar, and D. J Nutt Treatment of anxiety and depressive disorders in patients with cardiovascular disease BMJ, April 17, 2004; 328(7445): 939 - 943. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. M. H. Strik, J. Denollet, R. Lousberg, and A. Honig Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee for the ENRICHD Investigators Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial JAMA, June 18, 2003; 289(23): 3106 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Posternak, M. Zimmerman, G. I. Keitner, and I. W. Miller A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials Am J Psychiatry, February 1, 2002; 159(2): 191 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Ziegelstein Depression in Patients Recovering From a Myocardial Infarction JAMA, October 3, 2001; 286(13): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
